Medeon Biodesign, Inc. (6499.TWO) researches, develops, manufactures, and sells medical devices focused on minimally invasive surgeries and treatments; its core products include Cross-Seal, a large bore vascular closure system; Urocross, an expander system and retrieval sheath for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, a solution for orthopedic extremity injuries; ClickClean, a laparoscope lens shield device; AbClose, a trocar wound closure device to prevent port site herniation; and XFLO, a minimally invasive BPH treatment device. The company also provides contract development and manufacturing organization (CDMO) services through its subsidiary Medeologix Corporation, encompassing medical tubing extrusion, balloon forming, catheter processing, final assembly, packaging, and logistics; it further offers injection molding and components for medical devices. Founded in 2012 and headquartered at 7F, 116 HouGang Street, Taipei 11170, Taiwan, Medeon Biodesign operates primarily in the healthcare equipment sector, serving physicians, medtech entrepreneurs, and global medical companies with a presence in Taiwan, the United States (Sunnyvale, California), and international markets. Recent developments include U.S. FDA 510(k) clearance for the PUMA System and AbClose Trocar Wound Closure Device; FDA Investigational Device Exemption approval and first-in-human clinical trial clearance for Duett; positive interim clinical results for XFLO; FDA PMA approval for Cross-Seal with completed cGMP inspection; establishment of Medeologix with acquisitions of MediBalloon and Second Source Medical to expand CDMO capabilities; investments in Prodeon for the Mercury Project (URO-T01) and Delta Asia International Co. (now publicly listed as 6762.TWO); successful secondary public offering; and recent 2025 announcements of Urocross Expander System submission for FDA 510(k) clearance, Urocross Retrieval Sheath FDA 510(k) clearance, and cash capital increases.